Cargando…

Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence

Recurrent major depressive disorder (rMDD) is a relapsing-remitting disease with high morbidity and a 5-year risk of recurrence of up to 80%. This was a prospective pilot study to examine the potential diagnostic and prognostic value of targeted plasma metabolomics in the care of patients with rMDD...

Descripción completa

Detalles Bibliográficos
Autores principales: Mocking, Roel J. T., Naviaux, Jane C., Li, Kefeng, Wang, Lin, Monk, Jonathan M., Bright, A. Taylor, Figueroa, Caroline A., Schene, Aart H., Ruhé, Henricus G., Assies, Johanna, Naviaux, Robert K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801396/
https://www.ncbi.nlm.nih.gov/pubmed/33431800
http://dx.doi.org/10.1038/s41398-020-01182-w
_version_ 1783635565029097472
author Mocking, Roel J. T.
Naviaux, Jane C.
Li, Kefeng
Wang, Lin
Monk, Jonathan M.
Bright, A. Taylor
Figueroa, Caroline A.
Schene, Aart H.
Ruhé, Henricus G.
Assies, Johanna
Naviaux, Robert K.
author_facet Mocking, Roel J. T.
Naviaux, Jane C.
Li, Kefeng
Wang, Lin
Monk, Jonathan M.
Bright, A. Taylor
Figueroa, Caroline A.
Schene, Aart H.
Ruhé, Henricus G.
Assies, Johanna
Naviaux, Robert K.
author_sort Mocking, Roel J. T.
collection PubMed
description Recurrent major depressive disorder (rMDD) is a relapsing-remitting disease with high morbidity and a 5-year risk of recurrence of up to 80%. This was a prospective pilot study to examine the potential diagnostic and prognostic value of targeted plasma metabolomics in the care of patients with rMDD in remission. We used an established LC-MS/MS platform to measure 399 metabolites in 68 subjects with rMDD (n = 45 females and 23 males) in antidepressant-free remission and 59 age- and sex-matched controls (n = 40 females and 19 males). Patients were then followed prospectively for 2.5 years. Metabolomics explained up to 43% of the phenotypic variance. The strongest biomarkers were gender specific. 80% of the metabolic predictors of recurrence in both males and females belonged to 6 pathways: (1) phospholipids, (2) sphingomyelins, (3) glycosphingolipids, (4) eicosanoids, (5) microbiome, and (6) purines. These changes traced to altered mitochondrial regulation of cellular redox, signaling, energy, and lipid metabolism. Metabolomics identified a chemical endophenotype that could be used to stratify rrMDD patients at greatest risk for recurrence with an accuracy over 0.90 (95%CI = 0.69–1.0). Power calculations suggest that a validation study of at least 198 females and 198 males (99 cases and 99 controls each) will be needed to confirm these results. Although a small study, these results are the first to show the potential utility of metabolomics in assisting with the important clinical challenge of prospectively identifying the patients at greatest risk of recurrence of a depressive episode and those who are at lower risk.
format Online
Article
Text
id pubmed-7801396
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78013962021-01-21 Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence Mocking, Roel J. T. Naviaux, Jane C. Li, Kefeng Wang, Lin Monk, Jonathan M. Bright, A. Taylor Figueroa, Caroline A. Schene, Aart H. Ruhé, Henricus G. Assies, Johanna Naviaux, Robert K. Transl Psychiatry Article Recurrent major depressive disorder (rMDD) is a relapsing-remitting disease with high morbidity and a 5-year risk of recurrence of up to 80%. This was a prospective pilot study to examine the potential diagnostic and prognostic value of targeted plasma metabolomics in the care of patients with rMDD in remission. We used an established LC-MS/MS platform to measure 399 metabolites in 68 subjects with rMDD (n = 45 females and 23 males) in antidepressant-free remission and 59 age- and sex-matched controls (n = 40 females and 19 males). Patients were then followed prospectively for 2.5 years. Metabolomics explained up to 43% of the phenotypic variance. The strongest biomarkers were gender specific. 80% of the metabolic predictors of recurrence in both males and females belonged to 6 pathways: (1) phospholipids, (2) sphingomyelins, (3) glycosphingolipids, (4) eicosanoids, (5) microbiome, and (6) purines. These changes traced to altered mitochondrial regulation of cellular redox, signaling, energy, and lipid metabolism. Metabolomics identified a chemical endophenotype that could be used to stratify rrMDD patients at greatest risk for recurrence with an accuracy over 0.90 (95%CI = 0.69–1.0). Power calculations suggest that a validation study of at least 198 females and 198 males (99 cases and 99 controls each) will be needed to confirm these results. Although a small study, these results are the first to show the potential utility of metabolomics in assisting with the important clinical challenge of prospectively identifying the patients at greatest risk of recurrence of a depressive episode and those who are at lower risk. Nature Publishing Group UK 2021-01-11 /pmc/articles/PMC7801396/ /pubmed/33431800 http://dx.doi.org/10.1038/s41398-020-01182-w Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Mocking, Roel J. T.
Naviaux, Jane C.
Li, Kefeng
Wang, Lin
Monk, Jonathan M.
Bright, A. Taylor
Figueroa, Caroline A.
Schene, Aart H.
Ruhé, Henricus G.
Assies, Johanna
Naviaux, Robert K.
Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence
title Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence
title_full Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence
title_fullStr Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence
title_full_unstemmed Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence
title_short Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence
title_sort metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801396/
https://www.ncbi.nlm.nih.gov/pubmed/33431800
http://dx.doi.org/10.1038/s41398-020-01182-w
work_keys_str_mv AT mockingroeljt metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence
AT naviauxjanec metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence
AT likefeng metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence
AT wanglin metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence
AT monkjonathanm metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence
AT brightataylor metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence
AT figueroacarolinea metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence
AT scheneaarth metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence
AT ruhehenricusg metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence
AT assiesjohanna metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence
AT naviauxrobertk metabolicfeaturesofrecurrentmajordepressivedisorderinremissionandtheriskoffuturerecurrence